These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34011212)

  • 1. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naïve patients and in patients undergoing non-medical switch from originator.
    Giunta A; Zangrilli A; Bavetta M; Manfreda V; Pensa C; Bianchi L
    Curr Med Res Opin; 2021 Jul; 37(7):1099-1102. PubMed ID: 34011212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
    Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
    Blauvelt A; Leonardi CL; Gaylis N; Jauch-Lembach J; Balfour A; Lemke L; Hachaichi S; Brueckmann I; Festini T; Wiland P
    BioDrugs; 2021 Mar; 35(2):229-238. PubMed ID: 33651341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis.
    Becciolini A; Parisi S; Caccavale R; Bravi E; Lumetti F; Andracco R; Volpe A; Gardelli L; Girelli F; Di Donato E; Santilli D; Lucchini G; Ditto MC; Platè I; Arrigoni E; Mozzani F; Riva M; Marchetta A; Fusaro E; Sandri G; Salvarani C; Paroli M; Ariani A
    J Pers Med; 2022 Feb; 12(3):. PubMed ID: 35330335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
    Gisondi P; Geat D; Armeni P; Bellinato F; Maurelli M; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1579-1584. PubMed ID: 35466843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian model to analyse the association of comorbidities with biosimilar treatment retention in a non-medical switch scenario in patients with inflammatory rheumatic musculoskeletal diseases.
    Redeker I; Moustakis S; Tsiami S; Baraliakos X; Kiefer D; Andreica I; Buehring B; Braun J; Kiltz U
    Arthritis Res Ther; 2024 Sep; 26(1):155. PubMed ID: 39232829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
    Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Narbutt J; Philipp S; Spelman L; Weglowska J; Zhang N; Strober B
    J Am Acad Dermatol; 2017 Jun; 76(6):1093-1102. PubMed ID: 28291552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
    Feldman SR; Reznichenko N; Pulka G; Kingo K; George Galdava ; Berti F; Sobierska J; Dias R; Guenzi E; Hendrik Otto ; Haliduola HN; Kay R; Stroissnig H
    BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
    Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
    Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K; Bachelez H; Costanzo A; Foley P; Gooderham M; Kaur P; Philipp S; Spelman L; Zhang N; Strober B
    Br J Dermatol; 2017 Dec; 177(6):1562-1574. PubMed ID: 28755394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe.
    Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W
    Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
    Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A;
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease.
    Poquet-Jornet JE; Ibáñez-Sala I; Garrigues-Pelufo T; Munilla-Das A; Valdivia-Pérez A; Carrera-Hueso FJ
    Farm Hosp; 2024 Apr; ():. PubMed ID: 38570210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.